Controlled release formulation of divalproex sodium

US6511678B2 · kind B2 · utility

Assignee

• Abbott Laboratories · US

Inventors

• Yihong Qiu · Gurnee, US
• J. Daniel Bollinger · Libertyville, US
• Sandeep Dutta · Waukegan, US
• Howard Cheskin · Glencoe, US
• Kevin R. Engh · Kenosha, US
• Richard P. Poska · Mundelein, US

Key dates

• Filing date: Dec 22, 2000
• Grant date: Jan 28, 2003
• Expiry date: Dec 22, 2020

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K31/19
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A new oral polymeric controlled release formulation suitable for the once-a-day administration of valproate compounds, such as divalproex sodium, has been discovered. This formulation exhibits significant advantages over the sustained release valproate formulations of the prior art. This formulation minimizes the variation between peak and trough plasma levels of valproate over a 24 hour dosing period. This formulation follows a zero-order release pattern thus producing essentially flat plasma levels of valproate, once steady-state levels have been achieved. This results in a significantly lower incidence of side effects for patients consuming such a formulation.